Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × silmitasertib × Clear all
NCT02128282 2021-10-22

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Senhwa Biosciences, Inc.

Phase 1/2 Completed
127 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡